|
|
Vaccine Detail
|
MUC-1 Peptide Vaccine |
| Vaccine Information |
- Vaccine Name: MUC-1 Peptide Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007419
- Type: Other
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- MUC1
gene engineering:
- Type: Recombinant protein preparation
- Description: (Kato, 2014)
- Detailed Gene Information: Click Here.
- Description: A cancer vaccine comprised of a synthetic peptide derived from the mucin 1 (MUC1) antigen with potential antineoplastic activity. Upon administration, MUC1 peptide vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells positive for the MUC1 antigen, resulting in decreased tumor growth. Overexpressed on many tumor cells, MUC1 antigen, a mammary-type apomucin, is a high-molecular-weight transmembrane glycoprotein. (NCIT_C53290).
|
| Host Response |
|
|
| References |
Kato, 2014: Kato Y. [Efficacy of WT1 peptide-/MUC-1 peptide-pulsed dendritic cell therapy in 313 patients with a wide range of cancers]. Gan to kagaku ryoho. Cancer & chemotherapy. 2014; 41(10); 1280-1282. [PubMed: 25335717].
NCIT_C53290: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C53290]
|
|
